Senseonics Holdings Inc
AMEX:SENS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SENS's latest stock split occurred on Oct 20, 2025
The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.
Before the split, SENS traded at 0.408 per share. Afterward, the share price was about 8.47.
The adjusted shares began trading on Oct 20, 2025. This was SENS's 2nd stock split, following the previous one in Nov 10, 2015.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 27, 2026
|
M
|
Mitsubishi Logisnext Co Ltd
TSE:7105
|
1-for-22962728
/22962728
|
1529 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
|
Intsig Information Co Ltd
SSE:688615
|
1-for-1
x1
|
180.14 127.0214 CNY | 128 128 CNY |
|
Apr 27, 2026
|
|
Nousouken Corp
TSE:3541
|
1-for-550000
/550000
|
763 763 JPY | N/A |
|
Apr 27, 2026
|
F
|
Friendly Corp
TSE:8209
|
1-for-1355800
/1355800
|
312 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
I
|
IA Inc
KOSDAQ:038880
|
1-for-10
/10
|
135 1350 KRW | 1231 1231 KRW |
688615
3541
Senseonics Holdings Inc
Glance View
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.
